RyboDyn Raises $10 Million to Build the World's Best Map of Cancer Targets in the Dark Proteome

The capital raise arrives at a moment when conventional oncology pipelines are running into a structural ceiling. Established targets like EGFR, PD-L1, and HER2 each have hundreds of drugs in development, yet their reach is inherently limited. HER2, for example, is present in only roughly 15 to 20% of breast cancer patients. The majority are left without viable targeted immunotherapy options. RyboDyn's platform surfaced a novel target present in approximately 45% of HER2-negative breast cancer tumors it analyzed, including triple-negative patients who currently have few or no targeted treatment paths. That number tells the story of what the company is building toward.

At the center of RyboDyn's approach is RyboCypher, its proprietary sequencing and AI platform, which detects non-canonical RNA that go undetected by conventional next-generation sequencing. These RNA transcripts arise from genomic regions long considered non-functional, yet RyboDyn has shown they produce real, abundant, and often disease-specific proteins. The data generated by RyboCypher feed continuously into CypherAtlas, a queryable proprietary atlas now drawing from roughly 1,000 patient tumor samples across ten oncology indications. CypherAtlas currently catalogs more than 3 million conserved dark RNAs, more than 80,000 cryptic peptides identified empirically by mass spectrometry, and approximately 15,000 that are cancer-specific, with 117 validated Cryptic Targets to date. Mapping these peptides back to non-canonical RNAs in the CypherAtlas database enabled discovery of many full-length cryptic proteins (transcription factors, transmembrane proteins, cellular proteins and secreted proteins). The company describes it as the largest integrated dark transcriptome and proteome resource in the field.

The milestone that helped catalyze the round was the first-ever demonstration of ADC-mediated killing of tumor cells via a cryptic protein target in vitro, a proof-of-concept that gave investors concrete evidence the platform could move from discovery toward therapeutics.

External validation has come from multiple directions. A collaboration with Moffitt Cancer Center has confirmed that select Cryptic Targets are conserved across patient samples, absent in healthy tissue, and therapeutically actionable, using Moffitt's uniquely annotated tumor repository. Membership in NVIDIA's Inception Program is accelerating AI model development and data scaling. The company operates out of Lilly Gateway Labs in San Diego and participates in Lilly's AI TuneLabs consortium.

The seed round, backed by Genedant, SeaX, SOSV, Swell VC, Massive Tech Ventures, and P2V, will fund the transition from proof-of-concept work into scaled platform execution and the advancement of lead programs into IND-enabling studies. It will also support continued expansion of CypherAtlas across additional indications and patient cohorts, alongside biopharma partnership development.

Much of the human genome was written off as silent for decades. RyboDyn's argument, now backed by $10 million and a database of actionable cryptic targets, is that the silence was never quiet. Whether the platform can convert that biological complexity into clinical outcomes will be the defining test ahead. Ajjawi and Dambacher will share more about the company's progress and vision when RyboDyn takes the stage at SynBioBeta in San Jose this May.